MiroBio Ltd

MiroBio Ltd | 662 followers on LinkedIn. MiroBio's medicines activate natural mechanisms to regain control of over-active immune responses that drive disease. | MiroBio is founded by leading immunologists at the University of Oxford who have spent over 15 years focussed on understanding the mechanisms which underlie T-cell signalling. The technology is based on an IP portfolio of novel antibodies with the ability to activate inhibitory co-receptors on the surface of immune cells, with a deep mechanistic understanding, MiroBio is able to optimise these antibodies to create immune-modulatory therapies which have shown remarkable efficacy in preclinical models of disease. MiroBio is now building out the team and the platform looking for strong antibody-development expertise to take the lead compounds to clinical proof-of-concept.